ECI Biotech develops rapid, inexpensive infection diagnostics called ExpressDetect. Their primary product tests wounds for bacterial load in 10 minutes, compared to current methods that take 2-3 days. They are seeking $10M to fund production and sales of their wound diagnostic product. If successful, they project over $50M in revenue and profitability by 2012 by serving the $2.8B advanced wound care market.

1. Revolutionary Infection Diagnostics

2. ECI BIOTECH ECI Biotech is a Premier Developer of ExpressDetect® infection diagnostics. ExpressDetect ® diagnostics are simple, inexpensive, rapid, and safe. 3 Global Wound Care Companies Competing for Sales and Marketing Agreement. Currently raising $10M for CAPEX, Working Capital, and Operating Expense.

3. Team Anthony J. Bernardo , President & CEO 30+ years medical device experience (Inverness Medical innovations) Various senior management positions (M&A, GM, Operations, R&D, Business Development) with private and public companies BSEE/MSEE – Northeastern University (1974/1977) MBA – Boston College (1984) Mitchell C. Sanders , Executive VP & Founder 11 + years R&D and Business Development experience ($7M) BA Biology w Minor in Latin Literature – Boston University (1986) MS Biology /Ph.D. Biomedical Sciences – WPI (1988/1992) Two postdoctoral fellowships – MIT Whitehead Institute (1992-1997) Duane L. James , CFO 25 years progressive experience in accounting, finance, treasury and management for private and public multi-national companies (Inverness Medical innovations) BS Management/Finance – University of Massachusetts (1981) MBA – Rivier College (1995)

4. Market Size Advanced Wound Care is a $2.8 B Industry ECI’s Market Opportunity ($840M) 14M Chronic Wounds Treated Annually Each patient is checked 8-10 x for infection Biopsy Visual exam only Swab 35% 53% 12%

5. Unmet Need Wounds need to be tested for bacterial load before treatment Most patients are seen in 15 min (outpatient clinics) Visual Assessment Methods Inaccurate Current methods take 2-3 days to get results

6. Value Proposition Our test takes 10 minutes Low cost ($15 vs $75/225) Better treatment and faster healing outcomes Sen= 95% Spec = 90%

7. Second Product Opportunity Inexpensive, and safe enough for band-aids Sensor turns blue when infection is likely Featured on Medical Breakthroughs

8. Proof of Concept ECI Detects >98% of wound pathogens at 10 6 CFU/ml. Wound Healing Society mandates treatment at this level.

9. Competition ExpressDetect ® Antibody Visual Signs Culture Real Time    X Specificity   X  Inexpensive  X  X Broad Spectrum  X   Active Detection  X ? 

10. Intellectual Property Strong IP with 18 patent families issuing world-wide Additional design patents in preparation

11. Current Funding Corporate Development Funding (Current $0.3M) SBIR Grants Project Awarded Yeast Diagnostic $200,870 PoC Wound Diagnostic, Phase I $208,311 Therapeutic Agent for Periodontal Disease, years 1+2 $242,072 PoC Wound Diagnostic, Phase II $949,000 Project Pending Detecting Trauma Induced Wound Infections (DoD) $3,200,000 Yeast Diagnostic Phase II $1,000,000

12. Revenue Chronic Wound Opportunity for ECI = $840 Million 14M wounds; 4 tests/wound; $15/test 2008 2009 2010 2011 2012 Revenue (000) 793 515 2,453 12,691 23,859 EBITDA (1,049) (2,056) (1,412) 4,474 12,339 Pretax/Net Income (1,223) (2,693) (1,706) 4,015 9,146

13. Institutional Round

14. Timeline Financing: Q4-2008 Strategic partner relationships negotiated: Wound care PoC Q1-2009 Wound Dressing Q3-2009 Product Timing: PoC Wound Infection Diagnostic: Functional prototype: Q1-2009 Regulatory submission (FDA/CE): Q1-2010 Launch (USA or Europe): Q3-2010 Wound Dressing Diagnostic: Functional prototype: Q3-2009 Regulatory submission (FDA/CE): Q3-2010 Launch (USA): Q2-2011

15. Summary ExpressDetect ® - simple, inexpensive, rapid, & safe Large Markets ($B) Primary Products in Wound Care Pipeline (oral care & women’s health) Significant revenue >$50M and liquidity opportunity